Europska Unija - hrvatski - EMA (European Medicines Agency)

pfizer europe ma eeig - lorlatinib - karcinom, ne-malih stanica pluća - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

bontech research co d.o.o., split - slušni aparati

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

shimadzu d.o.o., zagreb - integrirani sustav za transferiranje, pregled, obradu i arhiviranje kog rtg dijagnostike

Europska Unija - hrvatski - EMA (European Medicines Agency)

molmed spa - alogenih t stanica genetski modificirani sa retrovirusni vektor kodiranje za skraćeni oblik ljudske nizak afinitet receptora faktora rasta živaca (Δlngfr) i herpes simplex virus timidin kinaze (hsv-tk mut2) - hematopoietic stem cell transplantation; graft vs host disease - antineoplastična sredstva - zalmoksis je indiciran kao dodatna terapija u haploidentical hematopoetskih matičnih stanica (hsct) odraslih bolesnika s visokog rizika hematoloških malignih bolesti.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

alcon farmaceutika d.o.o., zagreb - sonde za dijametriju dizajnirane za primjenu s constellatation, accurus, infiniti, laureate ili legacy oftalmološkim sistemima